Prostate Cancer Imaging

Seminars in Roentgenology

Volumn 41, Issue 2, 2006, Pages 139-149

  Kundra, Vikas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; CLINICAL FEATURE; DIGITAL RECTAL EXAMINATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK FACTOR; SEMINAL VESICLE; TUMOR BIOPSY; ULTRASOUND;

BIOPSY; BONE NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 33646503674     PISSN: 0037198X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ro.2006.03.001     Document Type: Article

References (63)

1. Cancer Facts & Figures, 2005. Atlanta, GA. American Cancer Society; 2005. Available at: http://www.cancer.org/docroot/STT/content/STT1xCancerFactsFigures2005.as p
2. McNeal J.E., Redwine E.A., Freiha F.S., et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 12 (1988) 897-906
3. Clements R. The role of transrectal ultrasound in diagnosing prostate cancer. Curr Urol Rep 3 3 (2002) 194-200
4. Makarov D.V., Sanderson H., Partin A.W., et al. Gleason score 7 prostate cancer on needle biopsy. is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. J Urol 167 6 (2002) 2440-2442
5. Catalona W.J., and Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152 5 Pt. 2 (1994) 1837-1842
6. Gerber G.S., Thisted R.A., Scardino P.T., et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276 8 (1996) 615-619
7. Catalona W.J., Hudson M.A., Scardino P.T., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer. receiver operating characteristic curves. J Urol 152 6 Pt. 1 (1994) 2037-2042
8. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 18 (1997) 1452-1455
9. Gretzer M.B., and Partin A.W. PSA markers in prostate cancer detection. Urol Clin North Am 30 4 (2003) 677-686
10. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 6 (2001) 843-848
11. Keetch D.W., Catalona W.J., and Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151 6 (1994) 1571-1574
12. Roehrborn C.G., Pickens G.J., and Sanders J.S. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 47 3 (1996) 347-352
13. Ellis W.J., and Brawer M.K. Repeat prostate needle biopsy. who needs it?. J Urol 153 5 (1995) 1496-1498
14. Presti Jr. J.C., Chang J.J., Bhargava V., et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies. results of a prospective clinical trial. J Urol 163 1 (2000) 163-166 discussion 166-167
15. Spencer J., and Golding S. CT evaluation of lymph node status at presentation of prostatic carcinoma. Br J Radiol 65 771 (1992) 199-201
16. Saitoh H., Yoshida K., Uchijima Y., et al. Two different lymph node metastatic patterns of a prostatic cancer. Cancer 65 8 (1990) 1843-1846
17. Vinnicombe S.J., Norman A.R., Nicolson V., et al. Normal pelvic lymph nodes. evaluation with CT after bipedal lymphangiography. Radiology 194 2 (1995) 349-355
18. Oyen R.H., Van Poppel H.P., Ameye F.E., et al. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy. prospective study of 285 patients. Radiology 190 2 (1994) 315-322
19. Nishijima Y., Uchida K., Koiso K., et al. Clinical significance of the vertebral vein in prostate cancer metastasis. Adv Exp Med Biol 324 (1992) 93-100
20. Bubendorf L., Schopfer A., Wagner U., et al. Metastatic patterns of prostate cancer. an autopsy study of 1,589 patients. Hum Pathol 31 5 (2000) 578-583
21. Yu K.K., and Hawkins R.A. The prostate. diagnostic evaluation of metastatic disease. Radiol Clin North Am 38 1 (2000) 139-157
22. Jewett H.J. Significance of the palpable prostatic nodule. J Am Med Assoc 160 10 (1956) 838-839
23. Smith D.S., and Catalona W.J. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45 1 (1995) 70-74
24. Dahnert W.F., Hamper U.M., Eggleston J.C., et al. Prostatic evaluation by transrectal sonography with histopathologic correlation. the echopenic appearance of early carcinoma. Radiology 158 1 (1986) 97-102
25. Griffiths G.J., Clements R., Jones D.R., et al. The ultrasound appearances of prostatic cancer with histological correlation. Clin Radiol 38 3 (1987) 219-227
26. Lee F., Torp-Pedersen S., Littrup P.J., et al. Hypoechoic lesions of the prostate. clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 170 1 Pt. 1 (1989) 29-32
27. Rifkin M.D., Sudakoff G.S., and Alexander A.A. Prostate. techniques, results, and potential applications of color Doppler US scanning. Radiology 186 2 (1993) 509-513
28. Newman J.S., Bree R.L., and Rubin J.M. Prostate cancer. diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 195 1 (1995) 86-90
29. Lavoipierre A.M., Snow R.M., Frydenberg M., et al. Prostatic cancer. role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol 171 1 (1998) 205-210
30. Kuligowska E., Barish M.A., Fenlon H.M., et al. Predictors of prostate carcinoma. accuracy of gray-scale and color Doppler US and serum markers. Radiology 220 3 (2001) 757-764
31. Cheng D., and Tempany C.M. MR imaging of the prostate and bladder. Semin Ultrasound CT MR 19 1 (1998) 67-89
32. Hricak H., Dooms G.C., McNeal J.E., et al. MR imaging of the prostate gland. normal anatomy. AJR Am J Roentgenol 148 1 (1987) 51-58
33. Hricak H., Dooms G.C., Jeffrey R.B., et al. Prostatic carcinoma. staging by clinical assessment, CT, and MR imaging. Radiology 162 2 (1987) 331-336
34. Schiebler M.L., Schnall M.D., Pollack H.M., et al. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 189 2 (1993) 339-352
35. Ikonen S., Kivisaari L., Vehmas T., et al. Optimal timing of post-biopsy MR imaging of the prostate. Acta Radiol 42 1 (2001) 70-73
36. Jager G.J., Ruijter E.T., van de Kaa C.A., et al. Local staging of prostate cancer with endorectal MR imaging. correlation with histopathology. AJR Am J Roentgenol 166 4 (1996) 845-852
37. Hering F., Rist M., Roth J., et al. Does microinvasion of the capsule and/or micrometastases in regional lymph nodes influence disease-free survival after radical prostatectomy?. Br J Urol 66 2 (1990) 177-181
38. Yu K.K., Hricak H., Alagappan R., et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging. multivariate feature analysis. Radiology 202 3 (1997) 697-702
39. Lange P.H., and Narayan P. Understaging and undergrading of prostate cancer. Argument for postoperative radiation as adjuvant therapy. Urology 21 2 (1983) 113-118
40. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 25 (2003) 2491-2499
41. Keller T.M., Michel S.C., Frohlich J., et al. USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors. preliminary results. Eur Radiol 14 6 (2004) 937-944
42. Sigal R., Vogl T., Casselman J., et al. Lymph node metastases from head and neck squamous cell carcinoma. MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR)-results of a phase-III multicenter clinical trial. Eur Radiol 12 5 (2002) 1104-1113
43. Rahmouni A., Yang A., Tempany C.M., et al. Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography. J Comput Assist Tomogr 16 6 (1992) 935-940
44. al-Rimawi M., Griffiths D.J., Boake R.C., et al. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostatic volume. Br J Urol 74 5 (1994) 596-600
45. Ikonen S., Kivisaari L., Tervahartiala P., et al. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol 42 4 (2001) 348-354
46. Swindle P., McCredie S., Russell P., et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 228 1 (2003) 144-151
47. Scheidler J., Hricak H., Vigneron D.B., et al. Prostate cancer. localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213 2 (1999) 473-480
48. Coakley F.V., Qayyum A., and Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170 6 Pt. 2 (2003) S69-S75 discussion S75-S76
49. Algra P.R., Bloem J.L., Tissing H., et al. Detection of vertebral metastases. comparison between MR imaging and bone scintigraphy. Radiographics 11 2 (1991) 219-232
50. Taoka T., Mayr N.A., Lee H.J., et al. Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy. AJR Am J Roentgenol 176 6 (2001) 1525-1530
51. Gold R.I., Seeger L.L., Bassett L.W., et al. An integrated approach to the evaluation of metastatic bone disease. Radiol Clin North Am 28 2 (1990) 471-483
52. Haukaas S., Roervik J., Halvorsen O.J., et al. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?. Br J Urol 79 5 (1997) 770-776
53. Manyak M.J., Hinkle G.H., Olsen J.O., et al. Immunoscintigraphy with indium-111-capromab pendetide. evaluation before definitive therapy in patients with prostate cancer. Urology 54 6 (1999) 1058-1063
54. Ponsky L.E., Cherullo E.E., Starkey R., et al. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 5 2 (2002) 132-135
55. Raj G.V., Partin A.W., and Polascik T.J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94 4 (2002) 987-996
56. Sodee D.B., Malguria N., Faulhaber P., et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 56 6 (2000) 988-993
57. Ellis R.J., Kim E.Y., Conant R., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 49 5 (2001) 1281-1286
58. Yao D., Trabulsi E.J., Kostakoglu L., et al. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 20 3 (2002) 211-218
59. Kwee S.A., Coel M.N., Lim J., et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 173 1 (2005) 252-255
60. Swindle P.W., Kattan M.W., and Scardino P.T. Markers and meaning of primary treatment failure. Urol Clin North Am 30 2 (2003) 377-401
61. Pucar D., Shukla-Dave A., Hricak H., et al. Prostate cancer. correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236 2 (2005) 545-553
62. Manzone T.A., Malkowicz S.B., Tomaszewski J.E., et al. Use of endorectal MR imaging to predict prostate carcinoma recurrence after radical prostatectomy. Radiology 209 2 (1998) 537-542
63. Silverman J.M., and Krebs T.L. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 168 2 (1997) 379-385